Abstract:Background Sarcopenia is characterized by loss of muscle mass and function and is associated with frailty, a syndrome with higher likelihood of falls, fractures, physical disability, and mortality. Both frailty and sarcopenia are known markers of shorter survival in various cancer patient populations. Low alanine aminotransferase (ALT), reflecting loss of muscle mass (sarcopenia), may be associated with greater frailty and shorter survival in multiple cancers. Objective To assess the potential association between low ALT and shorter survival among prostate cancer (PCa) patients and survivors. Design, setting, and participants This was a retrospective analysis of a historical cohort of PCa patients and survivors. Patients were defined as those still actively receiving PCa treatment, while those no longer receiving such treatment were classified as PCa survivors. Outcome measurements and statistical analysis ALT data were obtained from results for basic biochemical blood testing carried out for patients on their first hospital admission. Patients were divided into two groups: those with ALT ≥17 IU/l and those with ALT <17 IU/l. Univariate and multivariable analyses were conducted for between-group survival comparisons. Results and limitations We identified 9489 PCa records. The final study cohort with ALT data available included 4064 patients with ALT <40 IU/l. Of this cohort, 536 patients were actively receiving medical anticancer therapy for PCa. The mean age for the entire cohort was 74.6 yr (standard deviation 9.6) and the median ALT level was 19.28 IU/l; 1676 patients (41%) had low ALT (<17 IU/l). On univariate analysis, low ALT was associated with a 78% increase in mortality risk (95% confidence interval [CI] 1.62–1.97; p < 0.001). A sensitivity analysis of the 536 patients actively receiving medical anticancer treatment revealed that low ALT was associated with a 48% increase in mortality risk (95% CI 1.19–1.85; p = 0.001). In a multivariable model controlled for age, kidney disease, history of cerebrovascular event/transient ischemic attack, and baseline prostate-specific antigen, low ALT was still associated with a 35% increase in mortality risk (95% CI 1.12–1.63; p = 0.001). Limitations include the single-center, retrospective design. Conclusions Low ALT, which is indicative of sarcopenia and frailty, is associated with shorter survival among PCa patients and survivors and could potentially be used for treatment personalization. Patient summary We compared survival for prostate cancer patients and survivors according to their blood level of the protein alanine aminotransferase (ALT). Low ALT levels in the general population are associated with loss of muscle mass. We found that in our group of prostate cancer patients and survivors, the risk of death from any cause was higher for those with low ALT levels.

Association Between Low Alanine Aminotransferase Levels and Sarcopenia in Older Adults: A Cross-Sectional Study

Sarcopenia is Associated with the Presence of Nonalcoholic Fatty Liver Disease in Zhejiang Province, China: a Cross-Sectional Observational Study

Cross-sectional Analysis of the Association Between Serum Uric Acid Levels and Handgrip Strength among Chinese Adults over 45 Years of Age

High Serum AST/ALT Ratio and Low Serum INS*PA Product Are Risk Factors and Can Diagnose Sarcopenia in Middle-Aged and Older Adults

A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study

Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival

Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients

Sarcopenia prevalence and associated factors among older Chinese population: Findings from the China Health and Retirement Longitudinal Study

Retrospective Analysis of 1830 Patients

Effectiveness of sarcopenia screening markers in predicting out-of-hospital death in the oldest (≥80 years) older

Blood profiles of community-dwelling people with sarcopenia: analysis based on the China Health and Retirement Longitudinal Study

Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross‐sectional study in Korea

Sarcopenia Screening for Older Women with Low Body-Weight and Low Handgrip Strength is More Urgently Required

Sarcopenia-related Features and Factors Associated with Lower Muscle Strength and Physical Performance in Older Chinese: a Cross Sectional Study

Is Alanine Aminotransferase Associated with Osteopenia in Middle-Aged and Elderly Chinese?

The Association Between Sarcopenia and Prealbumin Levels Among Elderly Chinese Inpatients

The relationship between sarcopenia and related bioindicators and changes after intensive lifestyle intervention in elderly East-China populations

Association between sarcopenia and nutritional status and physical activity among community-dwelling Chinese adults aged 60 years and older.

Association between sarcopenia and cognitive function in older Chinese adults: Evidence from the China health and retirement longitudinal study

Higher Uric Acid Serum Levels Are Associated with Sarcopenia in West China: Results from the WCHAT Study

Possible-sarcopenic screening with disturbed plasma amino acid profile in the elderly